---
title: "Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Effects on other drugs"
description: "Formulary evidence on Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Effects on other drugs. Topics: CYP3A4 inhibition and induction, In vitro CYP3A4 and transporter inhibition, Ribociclib exposure with palazestrant 30 to 120 mg, Steady-state ribociclib parameters with and without palazestrant, and 4 further topics. 8 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description/effects-on-other-drugs"
published: "2026-11-15T20:23:25-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Effects on other drugs

<a id="heading-2.1.2.9.2"></a>

## 2.1.2.9.2 Effects of Palazestrant on Other Drugs

<a id="topic-2.1.2.9.2-1"></a>

### CYP3A4 inhibition and induction

> “Ribociclib is metabolized mainly by CYP3A4. Palazestrant is not a CYP3A4 inhibitor or inducer.”

Source: [Borges et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-003_12-5-23.pdf)

<a id="topic-2.1.2.9.2-2"></a>

### In vitro CYP3A4 and transporter inhibition

> “Low risk of transporter inhibition by compound 21 was determined by in vitro P-gp and BCRP assays (IC50 = 4 and >5 μM, respectively). No inhibitory activity was observed for the CYP 3A4 isoform (IC50 > 10 μM).”

Source: [Ng et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12163657/)

<a id="topic-2.1.2.9.2-3"></a>

### Ribociclib exposure with palazestrant 30 to 120 mg

> “Ribociclib 600 mg exposure is not affected by palazestrant doses ranging from 30 to 120 mg.”
> “When administered in combination with palazestrant, ribociclib exposure was within the reported range of the 600 mg dose single agent exposures at steady state.”

Source: [Borges et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-003_12-5-23.pdf)

<a id="topic-2.1.2.9.2-4"></a>

### Steady-state ribociclib parameters with and without palazestrant

| Steady-state parameter | Ribociclib single agent | Ribociclib in combination with palazestrant |
| --- | --- | --- |
| AUC0-24 ([h*ng/mL]/mg), GeoMean (GeoCV); N | “23,800 (66%); 54” | “25,400 (78%); 8” |
| Cmax (ng/mL/mg), GeoMean (GeoCV); N | “1,820 (62%); 57” | “1,860 (66%); 8” |
| Tmax (h), median (min–max); N | “2.4 (0.68–7.8); 57” | “4.0 (1.0–6.0); 8” |

Source: [Borges et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-003_12-5-23.pdf)

<a id="topic-2.1.2.9.2-5"></a>

### Ribociclib exposure at the September 2024 data cutoff

> “Palazestrant did not affect ribociclib 600 mg exposure when compared with published concentrations for single-agent ribociclib.”

Source: [Borges et al. (2024b)](https://ir.olema.com/static-files/dfb83ebb-df49-47a3-a585-ec416cc48954)

<a id="topic-2.1.2.9.2-6"></a>

### Ribociclib exposure at the July 2025 data cutoff

> “No significant drug-drug interaction was observed between palazestrant and ribociclib”
> “Palazestrant had no clinically meaningful effect on ribociclib 600 mg steady-state exposure when compared with published concentrations for single-agent ribociclib.”

Source: [Lin et al. (2025b)](https://ir.olema.com/static-files/e0c71c44-768f-4c6c-910a-167adf046b97)

<a id="topic-2.1.2.9.2-7"></a>

### Palbociclib exposure with palazestrant

> “There was no effect of palazestrant (30-120 mg) on palbociclib 125 mg exposure parameters.”
> “AUC(0-24)and Cmax ratios of combination therapy to monotherapy ranged from 96% to 107%.”

Source: [Chan et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-002_12-6-23.pdf)

<a id="topic-2.1.2.9.2-8"></a>

### Company summary of the palbociclib interaction data

> “There was no observed drug-drug interaction between palazestrant and palbociclib, and there was no induced metabolism or increase in exposure of either palbociclib or palazestrant when administered in combination.”

Source: [Olema Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526107169/olma-20251231.htm)

## Related pages
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Terms and abbreviations](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations.md)
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Product information and disease description](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Clinical evidence](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Economic information and modeling report](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: References](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references.md)
